Skip to main content
Premium Trial:

Request an Annual Quote

Pharma Spent $38.8B on R&D in 2004, a 12-Percent Jump; Breakdown on Genomic Spending Due Soon

NEW YORK, Feb. 18 (GenomeWeb News) - Member companies of the Pharmaceutical Research and Manufacturers of America collectively spent $38.8 billion on R&D last year in their drug-discovery and -development efforts, the organization said today.


The $38.8 billion in R&D represents a 12-percent increase over the $34.5 billion pharma collectively spent on R&D in 2003, and tops a steady increase in R&D over more thantwo decades, the organization said.  1980, PhRMA spent $2 billion on R&D.


A breakdown of the R&D spending by research categories, such as genomics and proteomics, is expected to be ready in a few weeks, a representative of PhRMA told GenomeWeb News. In terms of R&D spending by location, PhRMA member companies spent $30.6 billion, or 18 percent of domestic sales, on R&D within the United States, and an estimated $8.2 billion on R&D abroad.


PhRMA President and CEO Billy Tauzin said the US drug industry "is the world's largest source of investment in discovering better treatments [and exceeds] the international pharmaceutical industry and the National Institutes of Health."

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.